A collaborative program for safety intelligence The Safety Intelligence Program exploits BioWisdom's Sofia technology to deliver an Intelligence System that provides an unparalleled resource for drug safety benefit/risk assessment

Across the pharmaceutical industry, the challenge of developing and positioning medicines with the right benefit/risk equation, in a risk averse and external competitive environment is increasing. To better anticipate drug-related safety liability, there is an urgent need to gain a deeper understanding of mechanisms of serious adverse events that could potentially occur at any stage of a product's lifecycle.

The Safety Intelligence Program enables pharmaceutical industry professionals to formulate action plans and resolve drug-safety related biomedical issues, based on unbiased and comprehensive intelligence. In particular it allows;:

• Assessment of potential liability of novel chemical structures
• Assessment of potential risk of novel targets
• Optimization of chemical screening cascades
• Interpretation of unexpected pathology arising during preclinical or clinical studies
• Risk Management Planning
• Clinical trial design
• Interpretation of possible ‘signals' revealed through pharmacovigilance studies

Charter Membership to the Safety Intelligence Program is currently open to companies operating in the pharmaceutical industry. Charter Membership brings a number of advantages over those companies joining later. For more information about the Program or its Charter Membership, please contact sip@biowisdom.com